Consistent with this, in cancer, we have shown inhibition of CRIPTO with a soluble inhibitor, Alk4L75A-Fc, reduces primary and metastatic tumor burden in a breast cancer xenograft model. Here, CRIPTO is linked to metastatic neoplasm.